Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K. Edahiro Y, et al. Among authors: sato t. Int J Hematol. 2022 Aug;116(2):215-227. doi: 10.1007/s12185-022-03341-9. Epub 2022 Apr 16. Int J Hematol. 2022. PMID: 35430707 Clinical Trial.
Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K. Edahiro Y, et al. Among authors: sato t. Int J Hematol. 2022 Oct;116(4):642-643. doi: 10.1007/s12185-022-03440-7. Int J Hematol. 2022. PMID: 36029457 No abstract available.
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Jin J, Zhang L, Qin A, Wu D, Shao Z, Bai J, Chen S, Duan M, Zhou H, Xu N, Zhang S, Zuo X, Du X, Wang L, Li P, Zhang X, Li Y, Zhang J, Wang W, Shen W, Zagrijtschuk O, Urbanski R, Sato T, Xiao Z. Jin J, et al. Among authors: sato t. Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0. Exp Hematol Oncol. 2023. PMID: 37344895 Free PMC article.
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
Suo SS, Fu RF, Qin A, Shao ZH, Bai J, Chen SN, Duan MH, Zhou H, Xu N, Zhang SJ, Zuo XL, Du X, Wang L, Li P, Zhang XH, Wu DX, Li YN, Zhang JJ, Wang W, Shen WH, Zagrijtschuk O, Sato T, Xiao ZJ, Jin J. Suo SS, et al. Among authors: sato t. J Hematol. 2024 Apr;13(1-2):12-22. doi: 10.14740/jh1245. Epub 2024 Apr 9. J Hematol. 2024. PMID: 38644985 Free PMC article.
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.
Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih WJ, Zagrijtschuk O, Sato T, Shimoda K, Silver RT, Mesa R. Abu-Zeinah G, et al. Among authors: sato t. Ann Hematol. 2024 Sep;103(9):3573-3583. doi: 10.1007/s00277-024-05912-8. Epub 2024 Aug 15. Ann Hematol. 2024. PMID: 39145781 Free PMC article.
17,194 results
You have reached the last available page of results. Please see the User Guide for more information.